Sinovac Regains Nasdaq Listing Compliance Following 20-F Filing

Sinovac Biotech Ltd. (Nasdaq: SVA) announced on June 15, 2026, that it has regained compliance with Nasdaq Listing Rule 5250(c)(1). The company received a notification letter from The Nasdaq Stock Market LLC on June 10, 2026, confirming that it now meets the Nasdaq Global Market’s listing requirements. This restoration of compliance follows the company's filing of its annual report on Form 20-F for the fiscal year ended December 31, 2025, which was submitted on June 5, 2026. As a result of this filing, the previously requested hearing before the Hearings Panel has been canceled. However, Sinovac remains under a Mandatory Panel Monitor pursuant to Listing Rule 5815(d)(4)(B) until May 20, 2027, as per a prior compliance determination. Sinovac continues its operations as a leading biopharmaceutical provider in China, focusing on the development and commercialization of vaccines for infectious diseases, including influenza, hepatitis, and COVID-19.